GlaxoSmithKline and Takeda Pharmaceutical Co. Ltd. have agreed to include "black-box" warning labels on their diabetes drugs to caution patients about the risk of heart failure caused by the drugs, the FDA announced Tuesday. The new labels, which recommend close monitoring of patients taking Actos and Avandia, are separate from previous reports that link Avandia to heart attacks.

Related Summaries